The semaglutide impurity des-20-1-AEEA-SMT is a specific structural defect produced during the synthesis or degradation of semaglutide. Semaglutide is a GLP-1 receptor agonist, mainly used to treat type 2 diabetes and obesity. The impurity lacks the 1-AEEA modification fragment at the 20th position, which may affect the biological activity and stability of the drug. Strict monitoring of such impurities is of great significance to ensure the quality and safety of drugs.
Product Overview
Basic Description |
Structure and function: |
Three-letter sequence |
H-His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Lys(AEEA-γ-Glu-Octadecanedioic Acid)-Ile-Trp-Leu-Val-Lys-Gly-Asp-Val-Arg-Arg-Arg-Arg-Arg-Arg-Gly-CONH2 |
Single letter sequence |
HHAEGTFTSDVSSYLEGQAK(AEEA-γ-Glu-Octadecanedioic Acid)ITWLVLVKGDVRRAARRRRG-NH2 |
Molecular formula |
C185H290N49O57S |
Molecular weight |
4062.17 g/mol |
Product Attributes
purity |
>98% |
form |
Lyophilized powder |
Storage conditions |
Store at -20°C/-80°C away from light |